Mode
Text Size
Log in / Sign up

Plasma cytokines and CSF ROS measured in MS phenotypes show associations with disability and cognition.

Plasma cytokines and CSF ROS measured in MS phenotypes show associations with disability and cogniti…
Photo by Giuseppe Argenziano / Unsplash
Key Takeaway
Consider IL-8 and CSF ROS as potential biomarkers for disability and cognitive decline in MS phenotypes.

This multicenter longitudinal cohort study measured plasma cytokines (IL-6, IL-8, IFNα2) and cerebrospinal fluid (CSF) reactive oxygen species (ROS) in participants across MS phenotypes and other neurological disorders. Cohort 1 included 146 participants at baseline with 36 follow-up; Cohort 2 included 40 people with MS followed for 10 years. The comparator was RRMS and OND for Cohort 1 and longitudinal follow-up for Cohort 2.

Main results showed IL-6 and IFNα2 levels were reduced in PPMS-NA versus RRMS and OND, while CSF ROS levels were elevated. IL-8 levels were increased. IL-8 predicted disability and 10-year processing speed decline. IL-6 was initially linked to attention but later inversely associated with visuospatial and working memory. CSF ROS correlated with atrophy.

Safety and tolerability were not reported. Key limitations include that PPMS-NA is poorly understood. Practice relevance suggests IL-8 and CSF ROS may aid early stratification, with IL-6 relating to cognition, supporting therapies targeting oxidative stress and glia, though causality is not established.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundProgressive multiple sclerosis (MS) involves heterogeneous mechanisms, and primary progressive MS without inflammatory activity (PPMS-NA) is poorly understood.ObjectiveTo characterize the immune–oxidative profile of PPMS-NA and assess plasma IL-6, IL-8, IFNα2, and cerebrospinal fluid (CSF) reactive oxygen species (ROS) as predictors of disability and cognitive decline.MethodsWe conducted a multicenter longitudinal study with two cohorts. Cohort 1 included participants across MS phenotypes (n = 146 baseline; n = 36 follow-up) and other neurological disorders, measuring plasma cytokines and CSF ROS. Cohort 2 included 40 people with MS, followed for 10 years to assess associations with cognition. Outcomes were analyzed with multivariate models.ResultsPPMS-NA showed reduced IL-6 and IFNα2 but elevated CSF ROS versus RRMS and OND, reflecting low systemic inflammation and central oxidative stress. IL-8 increased, predicting disability and 10-year processing speed decline. IL-6 had time- and domain-specific effects: initially linked to attention, later inversely with visuospatial and working memory. CSF ROS correlated with atrophy, supporting oxidative stress as neurodegeneration driver.ConclusionPPMS-NA is a progressive MS subtype driven by oxidative and glial processes. IL-8 and CSF ROS are biomarkers for early stratification, and IL-6 relates to cognition, supporting therapies targeting oxidative stress and glia.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.